Research

Precision medicine researchers at UF Health are among the nation’s leading experts in studying pharmacogenomics and developing strategies to implement precision medicine into practice. Since 2011, UF Health researchers have been studying precision medicine from multiple angles and have been building an evidence-base which supports using genetic information to improve patient care. UF was among six sites chosen for the National Institutes of Health-funded Implementing GeNomics In pracTicE, or IGNITE, Network dedicated to supporting the implementation of genomics in health care and received more than $6 million in IGNITE I funding over five years. In 2018, UF was selected among five sites to lead IGNITE II and further advance the use of genomic information into medical practice.

$9+ million in total competitive funding

300+ peer-reviewed publications

16 full-time faculty

UF College of pharmacy

Center for Pharmacogenomics and Precision Medicine

The center focuses on improving patient outcomes through research, teaching and service focused on genetically-guided drug therapy decision making, drug discovery and drug development. Genotyping and other services are provided to the UF community and beyond.

Pharmacogenomics Team

IGNITE II Research network

Implementing Genomics into Clinical Practice

IGNITE II is a multi-institutional research network funded by the National Institutes of Health. Five institutions, including the University of Florida, have been funded to deliver personalized health care informed by genomics through IGNITE II.

IGNITE Modification

CLINICAL AND TRANSLATIONAL SCIENCE INSTITUTE

Precision Health Initiative Pilot Funding

The University of Florida Clinical and Translational Science Institute has partnered with the UF College of Pharmacy to create a new annual Precision Health Initiative Pilot Grant opportunity.

CTSI Building

CLINICAL TRIAL

Genotype-guided supportive care in treatment of cancer

All patients in this study will undergo genotyping for several genes that are associated with drug-metabolizing enzymes for drugs commonly used in supportive care regimens.

Thomas George